Effectiveness and safety of 12 mg versus 36 mg orforglipron doses for maintaining weight in people with obesity, with or without diabetes

Obesity is projected to affect about one billion adults by 2030.

• Orforglipron is an oral medication that may offer benefits for weight loss and metabolic health.
• Previous studies indicate its efficacy and safety, although they often involved shorter follow-up periods and mostly non-diabetic individuals.
• This analysis compares the two most commonly studied doses of Orforglipron (12 mg vs. 36 mg) directly.
• Outcomes assessed include weight, blood sugar levels, cardiometabolic health, and safety.

Simplified